Research Reports

Key takeaways

Mark Hilz, Chief Operating Officer, Corporate Secretary, and Board member, passed away on April 1, 2026, at age 67 after illness.

Hilz served on the Board since 2013 and as COO and Corporate Secretary since March 2022.

Company does not anticipate hiring a new COO in the foreseeable future following MyoVista Insights launch and wavECG FDA submission.

No expected changes to business, operations, or FDA commercialization plans due to Hilz's passing.

Full analysis

The departure of Mark Hilz, a long-serving executive and director since 2013, represents a significant leadership transition for HeartSciences Inc., particularly given his dual roles as COO and Corporate Secretary since March 2022. However, the company explicitly states no material impact on operations, citing the timely launch of MyoVista Insights software and the December 2025 FDA 510(k) submission for MyoVista wavECG device. Investors should note the company's confidence in proceeding without a COO replacement, suggesting internal capabilities or redistributed responsibilities can sustain commercialization efforts.

HSCS · HeartSciences Inc.

Summary

Key takeaways

Full analysis